Charles Schwab Investment Management Inc. Purchases 2,836 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Charles Schwab Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 0.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 418,980 shares of the biopharmaceutical company’s stock after purchasing an additional 2,836 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $74,201,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Parnassus Investments LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $6,862,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 688,228 shares of the biopharmaceutical company’s stock worth $121,885,000 after buying an additional 15,831 shares in the last quarter. Moody Aldrich Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $404,000. Oppenheimer & Co. Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 93 shares during the period. Finally, Clearstead Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 197.6% during the third quarter. Clearstead Advisors LLC now owns 4,518 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 3,000 shares during the period. 93.98% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $169.34 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $148.10 and a 1 year high of $227.91. The firm has a market cap of $21.25 billion, a PE ratio of -40.90 and a beta of 0.43. The stock has a fifty day moving average price of $183.67 and a 200-day moving average price of $179.31.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $175.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday. Piper Sandler upped their target price on Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the stock an “overweight” rating in a research report on Thursday, December 14th. Finally, JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $230.95.

View Our Latest Analysis on ALNY

Insider Activity

In other news, Director Michael W. Bonney sold 30,000 shares of the stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the completion of the transaction, the director now owns 16,029 shares in the company, valued at approximately $3,125,655. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.40% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

See Also

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.